Business
Digipath's Dr. Cindy Orser Featured in Forbes Article on Cannabis Strains/Cultivars
Digipath's Dr. Cindy Orser Featured in Forbes Article on Cannabis Strains/Cultivars.
About this update from Hypha Labs, Inc.
[{"type":"text","content":"\n\n\n\nDigipath's Dr. Cindy Orser Featured in Forbes Article on Cannabis Strains/Cultivars\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nDigipath's Dr. Cindy Orser Featured in Forbes Article on Cannabis Strains/Cultivars\nPR Newswire\nLAS VEGAS, June 13, 2019\n\n\n\nLAS VEGAS, June 13, 2019 /PRNewswire/ -- Digipath, Inc. (OTCQB: DIGP) (\"DIGP\" or the \"Company\"), a service-oriented independent testing laboratory, data analytics and media firm focused on the developing cannabis and hemp markets, is pleased to report that Chief Science Officer and Board member Dr. Cindy Orser was cited in an important new article in Forbes titled \"Game Of Genomes: The Battle For The King Of Cannabis Strains Is Just Heating Up.\"\n\n \n \n\n \nThe article, written by Forbes contributor Andre Bourque, addresses the messy nomenclature of the current cannabis market wherein an imprecise system of non-scientific names is used to identify and sell cannabis strains, or more accurately cannabis cultivars.\nMr. Bourque refers to Dr. Orser and her colleague Dr. Philippe Henry's assertion that \"the cannabis consumer patient often times has no real idea of the composition, consistency or comparability of the cannabis product that they purchase,\" in their previous peer-reviewed publication \"Making Sense of Cannabis Strains through Chemometrics,\" in Cannabis Science & Technology.\n\"We are pleased to see this timely article draw attention to the issues faced by today's cannabis consumers resulting from incorrect taxonomy and naming conventions. This is yet another example of Drs. Orser and Henry's transformative work to illustrate and solve this problem,\" stated Todd Denkin, CEO, Digipath. \"With Dr. Orser on board as a true market leader in the science of cannabis, Digipath is committed to improving the way we cultivate, study, test and use cannabis.\"\nAbout Digipath, Inc. (OTCQB: DIGP)Digipath, Inc., supports the cannabis industry's best practices for reliable testing, data acquisition, cannabis education and training, and brings unbiased cannabis news coverage to the cannabis ind...